Skip to main content
Veterinary Medicines

Zodon 150 mg Chewable Tablets for Dogs

Authorised
  • Clindamycin hydrochloride

Product identification

Medicine name:
ZODON 150 MG CHEWABLE TABLETS FOR DOGS
Zodon 150 mg Chewable Tablets for Dogs
Active substance:
  • Clindamycin hydrochloride
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Clindamycin hydrochloride
    162.90
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Chewable tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01FF01
Authorisation status:
  • Valid
Authorised in:
  • United Kingdom (Northern Ireland)
Package description:
  • Cardboard box of 16 tablets containing 2 blisters of 8 tablets
  • Cardboard box of 96 tablets containing 12 blisters of 8 tablets
  • Cardboard box of 240 tablets containing 30 blisters of 8 tablets
  • Cardboard box of 8 tablets containing 1 blister of 8 tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Ceva Animal Health Limited
Marketing authorisation date:
Manufacturing sites for batch release:
  • Ceva Sante Animale
Responsible authority:
  • European Medicines Agency
Authorisation number:
  • Vm 15052/4126
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0362/002
Concerned member states:
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."